MedTrace Logo

Myopia Progression and the Effect of 7-Methylxanthine

NCT00263471 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2005-12-14

No results posted yet for this study

Summary

7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. The study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.

Conditions

  • Myopia

Interventions

DRUG

7-methylxanthine

Sponsors & Collaborators

  • Generalkonsul Einar Høyvalds Fond

    collaborator UNKNOWN

  • Jørgen Bagenkop Nielsens Myopi-Fond

    collaborator UNKNOWN

  • Chr. Andersen og hustru Ingeborg Andersen, f. Schmidts legat (fond) oprettet af deres datter, frk. Lilli Ellen Andersen.

    collaborator UNKNOWN

  • Trier Research Laboratories

    lead OTHER

Principal Investigators

  • Klaus Trier, MD · Trier Research Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2006-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263471 on ClinicalTrials.gov